Moderna Launches Early-Stage Clinical Trial Of Its mRNA-Based HIV Vaccine

Moderna has administered the first doses of its mRNA-based HIV vaccine to volunteers in a clinical trial, the biotechnology company announced late last week.

The trial is being conducted in partnership with the nonprofit International AIDS Vaccine Initiative (IAVI). Researchers are testing whether an mRNA-based vaccine, which uses the same technology as Moderna’s successful COVID-19 vaccine, can deliver the instructions for HIV-specific antigens and induce certain immune responses.

The first participants in the Phase I trial were given doses at George Washington University School of Medicine and Health Sciences in Washington, D.C., according to a company statement.

“We are tremendously excited to be advancing this new direction in HIV vaccine design with Moderna’s mRNA platform,” Dr. Mark Feinberg, president and CEO of IAVI, said in a statement. “The search for

READ MORE OF THIS POST AT The Gaily Grind